Trial Profile
A Study to Evaluate the Efficacy and Tolerability of Everolimus following the First VEGF-targeted Therapy in Patients with Metastatic Renal Cell Carcinoma (mRCC)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Feb 2016
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms CHANGE
- 10 Feb 2016 Planned number of patients changed to 360.
- 09 Dec 2015 New trial record